Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tiny dose of atropine dry up watery eyes?

NCT ID NCT07816224

Symptom relief Sponsor: Rehan Ahmed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether very low-dose atropine eye drops reduce excessive tearing in adults who wipe their eyes at least twice a day. Each participant uses two drops, one at a time: atropine 0.005% and an identical-looking drop with no active ingredient. They use each drop once nightly for 7 days, with about 2 weeks between the two periods, and neither the participants nor the study doctors know which drop is which. The main measure is how often participants need to wipe their eyes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atropine sulfate ophthalmic solution 0.005%
What this could lead to
If it works, low-dose atropine drops could offer a simple nightly option for adults whose eyes water constantly and who currently have few reliable treatments.
What could go wrong
The trial is small, with about 12 to 18 participants, and each treatment lasts only 7 days, so any benefit may be short-lived or not hold up in larger studies. Atropine can cause blurred vision, light sensitivity, or dry eye, and the drops may not help tearing caused by blocked tear ducts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 16 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults 18 years of age or older * Symptomatic epiphora (unilateral or bilateral) with tearing requiring eyelid wiping or dabbing at least 2 times per day (Munk score ≥2) * Epiphora attributed to functional/idiopathic, gustatory, environmental, or lacrimal outflow (e.g., nasolacrimal duct obstruction, punctal stenosis) etiology * Visual acuity of 20/200 or better in at least one eye (with habitual correction or pinhole) * Willing and able to self-administer eye drops nightly for 7 days in each of two treatment periods and attend all study visits * Prior use of topical atropine permitted if at least 10 days have elapsed since the last dose Exclusion Criteria: * Clinically significant dry eye disease, or tearing judged to be a reflex response to ocular surface disease, blepharitis, or other ocular surface irritation * Regular use of artificial tears, ocular lubricants, or dry eye medications, or unwillingness to stop them during the study * Active or recent (within 30 days) ocular infection, or active dacryocystitis * Current use of ophthalmic anticholinergic agents (unless stopped at least 10 days before Visit 1) * Hypersensitivity to atropine, other anticholinergics, or any component of the formulation * Angle-closure glaucoma or narrow anterior chamber angles * Pregnancy or breastfeeding * Participation in another interventional study within 30 days * Any condition or medication that, in the investigator's judgment, would interfere with study assessments or subject safety

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epiphora are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

excessive tearing lacrimal apparatus disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epiphora

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.